Ocugen guides OCU400 Phase 3 topline for Q1 2027, BLA filing target Q2 2027

Ocugen's October investor deck, filed as an 8-K exhibit on Oct 15, guides topline data for the Phase 3 liMeliGhT trial of OCU400 in retinitis pigmentosa for Q1 2027, with a BLA filing target of Q2 2027. The pivotal trial has 140 patients enrolled in a 2:1 treatment vs untreated control design.

Detected & updated continuously · Source: Nebula